Japan’s largest drugmaker Takeda today announced that Orzeyful (oveporexton) is now available in Japan and China for the ...
The UK National Institute of Health and Care Excellence (NICE) has issued negative final guidance for the use of Roche’s ...
French clinical-stage vaccine company Osivax said its Phase IIb field efficacy trial of OVX836, a nucleoprotein-based ...
Amsterdam-based precision oncology company iOnctura has appointed Paul Sekhri as chair of its board, with immediate effect, as it prepares for late-stage development of its lead drug, roginolisib. He ...
The US Food and Drug Administration (FDA) approved Anktiva (nogapendekin alfa inbakicept-pmln) from Altor BioSciences, an ...
For someone receiving Casgevy (exagamglogene autotemcel), gene editing involves much more than an infusion. Blood stem cells ...
Life science investor Syncona announces that it has committed $10.1 million (£7.5 million) to a $310 million (£230 million) ...
US biotech company Verastem Oncology (Nasdaq: VSTM) has priced a $250 million offering alongside new results for its ...
French pharma major Sanofi (Euronext: SAN) must correct potentially misleading messages about a rival flu vaccine and ...
The US regulator, the Food and Drug Administration (FDA), has launched an initiative to reshape rare disease drug development ...
Vir Biotechnology shares jumped nearly 10% in pre-market trading following a major licensing agreement with Gilead Sciences ...
Partner Therapeutics (PTx) is a USA-based cancer start-up that was set up in January 2018 by the former Merrimack chief executive, Robert Mulroy, and Debasish Roychowdhury, the ex-chief medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results